Amylyx Pharmaceuticals, Inc.AMLXNASDAQ
Loading
| Metric | Dec 21 | Dec 22 | Dec 23 |
|---|---|---|---|
| Revenue | 0 | 22 | 381 |
| Gross Profit | 0 | 19 | 355 |
| Operating Income | -83 | -201 | 39 |
| Net Income | -88 | -198 | 49 |
| EBITDA | -83 | -201 | 40 |
| EPS Diluted | -1.52 | -2.98 | 0.70 |
| Metric | Dec 21 | Dec 22 | Dec 23 |
|---|---|---|---|
| Cash & Equivalents | 50 | 63 | 170 |
| Total Current Assets | 105 | 382 | 465 |
| Total Assets | 106 | 391 | 517 |
| Total Current Liabilities | 17 | 47 | 82 |
| Total Liabilities | 257 | 51 | 84 |
| Total Equity | -151 | 341 | 433 |
| Total Debt | 0 | 6 | 4 |
| Net Debt | -50 | -56 | -166 |
| Metric | Dec 21 | Dec 22 | Dec 23 |
|---|---|---|---|
| Operating Cash Flow | -75 | -180 | 12 |
| Capital Expenditure | -0 | -3 | -1 |
| Free Cash Flow | -75 | -182 | 11 |
| Stock-Based Comp | 3 | 22 | 37 |
| Net Change in Cash | 37 | 13 | 108 |